Skip to main content

Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.

Publication ,  Journal Article
To, WC; Wood, BG; Krauss, JC; Strome, M; Esclamado, RM; Lavertu, P; Dasko, D; Kim, JA; Plautz, GE; Leff, BE; Smith, V; Sandstrom-Wakeling, K; Shu, S
Published in: Arch Otolaryngol Head Neck Surg
October 2000

OBJECTIVE: To evaluate the feasibility and toxic effects of systemic adoptive T-cell immunotherapy in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN). DESIGN: Nonrandomized phase 1 clinical trial. SETTING: Academic tertiary care hospital. PATIENTS: Between April 1, 1996, and September 30, 1998, 17 patients with confirmed recurrent and metastatic SCC of the upper aerodigestive tract were enrolled. Two patients did not receive T cells because of poor vaccine response. Fifteen patients were successfully treated with T-cell immunotherapy. INTERVENTION: Patients were vaccinated on the thigh with irradiated autologous tumor cells admixed with granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by 3 additional daily injections of GM-CSF at the vaccination site. Eight to 10 days later, tumor cell vaccine-draining inguinal lymph nodes were resected, and lymph node lymphocytes were activated with staphylococcal enterotoxin A and expanded in interleukin 2 in vitro. Resulting cultured cells were infused into patients peripherally on an outpatient basis. RESULTS: Toxic effects of infusion were limited to grade 2 reactions in 3 of 16 treatments. One patient required overnight hospitalization for fever and emesis. Median cell expansion was 37 times (range, 4-416 times), and median cell dose was 7.5 x 10(9) (range, 1.3 x 10(8) to 4.2 x 10(10)). Infused cells were predominantly CD3+ (>97%), being a mixture of CD4+ and CD8+ cells. Three patients demonstrated stabilization of previously progressive disease. Two patients experienced favorable clinical courses after adoptive T-cell transfer, including 1 patient with no evidence of disease 4 years after surgical resection of a vertebral body metastasis. CONCLUSIONS: Adoptive immunotherapy is a technically feasible and safe treatment with low toxicity and may demonstrate therapeutic activity in patients with unresectable SCCHN.

Duke Scholars

Published In

Arch Otolaryngol Head Neck Surg

DOI

ISSN

0886-4470

Publication Date

October 2000

Volume

126

Issue

10

Start / End Page

1225 / 1231

Location

United States

Related Subject Headings

  • Treatment Outcome
  • T-Lymphocytes
  • Otorhinolaryngology
  • Neoplasm Recurrence, Local
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Immunotherapy, Adoptive
  • Humans
  • Head and Neck Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
To, W. C., Wood, B. G., Krauss, J. C., Strome, M., Esclamado, R. M., Lavertu, P., … Shu, S. (2000). Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg, 126(10), 1225–1231. https://doi.org/10.1001/archotol.126.10.1225
To, W. C., B. G. Wood, J. C. Krauss, M. Strome, R. M. Esclamado, P. Lavertu, D. Dasko, et al. “Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.Arch Otolaryngol Head Neck Surg 126, no. 10 (October 2000): 1225–31. https://doi.org/10.1001/archotol.126.10.1225.
To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1225–31.
To, W. C., et al. “Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.Arch Otolaryngol Head Neck Surg, vol. 126, no. 10, Oct. 2000, pp. 1225–31. Pubmed, doi:10.1001/archotol.126.10.1225.
To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, Dasko D, Kim JA, Plautz GE, Leff BE, Smith V, Sandstrom-Wakeling K, Shu S. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1225–1231.

Published In

Arch Otolaryngol Head Neck Surg

DOI

ISSN

0886-4470

Publication Date

October 2000

Volume

126

Issue

10

Start / End Page

1225 / 1231

Location

United States

Related Subject Headings

  • Treatment Outcome
  • T-Lymphocytes
  • Otorhinolaryngology
  • Neoplasm Recurrence, Local
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Immunotherapy, Adoptive
  • Humans
  • Head and Neck Neoplasms